• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)

    10/6/22 12:24:15 PM ET
    $NOTV
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $NOTV alert in real time by email
    SC 13D/A 1 brhc10042757_sc13da.htm SC 13D/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13D
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
    Inotiv, Inc.

    (Name of Issuer)
    Common Shares, no par value per share

    (Title of Class of Securities)
    45783Q100

    (CUSIP Number)
    Jermyn Street Associates LLC
    660 Madison Avenue, 15th Floor
    New York, New York 10065
    (212) 813-9203
    with copies to:
    Kimberly C. Petillo-Décossard
    Ross Sturman
    Cahill Gordon & Reindel LLP
    32 Old Slip
    New York, New York 10005
    (212) 701-3265

    (Name, Address and Telephone Number of Person Authorized to Receive
    Notices and Communications)
    September 21, 2022

    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rules 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 45783Q100

    1
    NAMES OF REPORTING PERSONS
     
     
    Jermyn Street Associates LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☑
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    State of Nevada
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    1,378,280 shares
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0 shares
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    1,378,280 shares
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0 shares
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,378,280 shares
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    5.4%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No. 45783Q100

    1
    NAMES OF REPORTING PERSONS
     
     
    Andrew H. Baker
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☑
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United Kingdom
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    1,378,280 shares
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    0 shares
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    1,378,280 shares
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    0 shares
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,378,280 shares
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    5.4%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    CONTINUATION PAGES TO SCHEDULE 13D

    This Amendment No. 2 amends the Schedule 13D filed with the Securities and Exchange Commission on November 15, 2021, as amended by Amendment No. 1 to the Schedule 13D filed on July 5, 2022 (together, the “Schedule 13D”) jointly by Jermyn Street Associates LLC, a Nevada limited liability company (“JSA”) and Andrew Baker, a citizen of the United Kingdom and the sole Manager of JSA. Terms used but not defined herein have the meaning given in the Schedule 13D.

    Item 5
    Interest in Securities of the Issuer

    Items 5(a), 5(b) and 5(c) of the Schedule 13D are hereby amended and restated in their entirety as follows:

    (a)-(b):
    All percentages set forth in this Statement are based on an aggregate of 25,593,313 Shares outstanding, which is the number of Shares outstanding as of August 3, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on August 12, 2022.

    As of the date of this filing, JSA is the beneficial owner of 1,378,280 Shares owned directly by JSA, representing approximately 5.4% of the outstanding Shares. Each of JSA, Jermyn Street Associates II LLC, a Nevada limited liability company (“JSA II”) and Jermyn Street Capital LLC, a Nevada limited liability company (“JSC”) is a party to the Shareholders Agreement (as defined below) which requires, among other things, that JSA II and JSC vote their Shares for the director nominee designated by JSA. As of the date of this filing, based on information provided by JSA II and JSC, JSA II and JSC no longer directly own any Shares and are no longer subject to the voting arrangements under the Shareholders Agreement. Therefore, JSA II and JSC no longer may be deemed to be members of a “group” with JSA for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Act”).

    As of the date of this filing, Mr. Baker is the direct owner of 0 Shares and the beneficial owner of 1,378,280 Shares representing approximately 5.4% of the outstanding Shares, which Shares are owned directly by JSA. Mr. Baker is the sole Manager of JSA and, as such, has the sole power to vote, direct the vote, dispose of or direct the disposition of the Shares directly owned by JSA. Accordingly, Mr. Baker may be deemed to beneficially own the Shares that are directly owned by JSA. Mr. Baker expressly disclaims beneficial ownership of the Shares owned by JSA for all other purposes.

    JSA is a party to that certain Shareholders Agreement, dated as of November 5, 2021 (the “Shareholders Agreement”), among the Issuer and certain stockholders of Envigo. The Shareholders Agreement requires, among other things, that the shareholders party thereto vote their Shares for directors that are designated in accordance with the provisions of the Shareholders Agreement. By virtue of the Shareholders Agreement and the obligations and rights thereunder, JSA and the other shareholders party to the Shareholders Agreement may be deemed to constitute a “group” for purposes of Section 13(d) of the Act, and JSA may be deemed to beneficially own Shares beneficially owned by such other shareholders. This filing shall not be deemed an admission that JSA and any of such other shareholders constitute a “group” for purposes of Section 13(d) of the Act and the Reporting Persons expressly disclaim beneficial ownership over any Shares owned by the other shareholders party to the Shareholders Agreement that the Reporting Persons may be deemed to beneficially own solely by reason of the Shareholders Agreement. Shares owned by other shareholders party to the Shareholders Agreement are not included in this Statement.

    As of the date of this filing, based on the Schedule 13D/A dated September 20, 2022 of Savanna Holdings, LLC (“Savanna Holdings”), Savanna Holdings no longer holds any Shares and is no longer subject to the voting arrangements under the Shareholders Agreement. Accordingly, Savanna Holdings no longer may be deemed to constitute a “group” with JSA and the other shareholders party to the Shareholders Agreement for purposes of Section 13(d) of the Act.

    (c)          On or about September 21, 2022, JSA distributed 200,047 Shares to one of its members, for no consideration. On or about September 30, 2022, JSC distributed an aggregate of 499,095 Shares to certain of its members for no consideration.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: October 6, 2022
     
       
    JERMYN STREET ASSOCIATES LLC
    /s/ Andrew Baker
     
    Name:
    Andrew Baker
     
    Title:
    Authorized Signatory

    ANDREW BAKER
    /s/ Andrew Baker
     
    Name:
    Andrew Baker
     
    Title:
    Authorized Signatory



    Get the next $NOTV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NOTV

    DatePrice TargetRatingAnalyst
    5/14/2024$11.50 → $3.75Buy → Hold
    Jefferies
    2/9/2024$3.00 → $11.50Hold → Buy
    Jefferies
    7/20/2023$9.00Overweight
    Wells Fargo
    1/19/2023$10.00 → $8.00Buy → Hold
    Jefferies
    1/11/2023$4.00 → $10.00Hold → Buy
    Lake Street
    11/18/2022$60.00 → $7.00Buy → Hold
    Lake Street
    10/4/2022$27.00Buy
    Jefferies
    1/31/2022$60.00Buy
    Lake Street
    More analyst ratings

    $NOTV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update

      —  Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million—  Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million—  Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q2 FY 2025") ended March 31, 2025 and six months ("YTD FY 2025") ended March 31, 2025. Revenue by Segment (in millions of USD)   Three Months EndedMarch 31, %change Six Mo

      5/7/25 4:05:00 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025

      WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, on Wednesday, May 7, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-245-3047 (Domestic)1-203-518-9765 (International)INOTIV

      4/23/25 4:05:00 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Inotiv Reports First Quarter Financial Results for Fiscal 2025 and Provides Business Update

      Enhanced liquidity by $27.5 million through the issuance of 6.9 million common sharesFirst quarter fiscal 2025 revenue declined 11.5% to $119.9 millionConference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q1 FY 2025") ended December 31, 2024. Revenue by Segment (in millions of USD)  Three Months EndedDecember 31, % change   2024  2023    (unaudite

      2/5/25 4:05:00 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NOTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Inotiv downgraded by Jefferies with a new price target

      Jefferies downgraded Inotiv from Buy to Hold and set a new price target of $3.75 from $11.50 previously

      5/14/24 8:01:45 AM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Inotiv upgraded by Jefferies with a new price target

      Jefferies upgraded Inotiv from Hold to Buy and set a new price target of $11.50 from $3.00 previously

      2/9/24 6:17:55 AM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Wells Fargo initiated coverage on Inotiv with a new price target

      Wells Fargo initiated coverage of Inotiv with a rating of Overweight and set a new price target of $9.00

      7/20/23 7:55:03 AM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NOTV
    Leadership Updates

    Live Leadership Updates

    See more
    • Universal Display Corporation Announces the Appointment of New Board Members

      Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti

      3/7/24 4:05:00 PM ET
      $BDN
      $NOTV
      $OLED
      $RMTI
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Inotiv, Inc. Announces Changes to its Board Composition

      WEST LAFAYETTE, Ind., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV), a leading contract research organization, today announced the appointment of Terry Coelho to its Board of Directors. Ms. Coelho is replacing Richard A. Johnson PhD, who is leaving the Board as part of the Board's succession planning. Ms. Coelho was also appointed to serve as a member of the Compensation Committee and the Audit Committee, and as a member and the Chair of the Nominating/Corporate Governance Committee of the Board. Ms. Coelho is the CFO at Gamida Cell Ltd., a public, commercial stage biotech company. Previously, Ms. Coelho was Executive Vice President, CFO and Chief Business Development Offic

      10/16/23 8:00:00 AM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NOTV
    SEC Filings

    See more
    • SEC Form 10-Q filed by Inotiv Inc.

      10-Q - Inotiv, Inc. (0000720154) (Filer)

      5/7/25 8:28:27 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Inotiv Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Inotiv, Inc. (0000720154) (Filer)

      5/7/25 4:10:58 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Inotiv Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Inotiv, Inc. (0000720154) (Filer)

      3/13/25 4:50:23 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NOTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Landman David bought $99,998 worth of shares (23,529 units at $4.25), increasing direct ownership by 15% to 176,851 units (SEC Form 4)

      4 - Inotiv, Inc. (0000720154) (Issuer)

      12/23/24 9:47:13 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Chief Operating Officer Beattie John Gregory bought $142,500 worth of shares (30,000 units at $4.75), increasing direct ownership by 23% to 161,761 units (SEC Form 4)

      4 - Inotiv, Inc. (0000720154) (Issuer)

      12/12/24 6:46:46 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Brown Nigel bought $31,950 worth of shares (7,500 units at $4.26), increasing direct ownership by 13% to 65,537 units (SEC Form 4)

      4 - Inotiv, Inc. (0000720154) (Issuer)

      12/10/24 4:13:30 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NOTV
    Financials

    Live finance-specific insights

    See more
    • Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update

      —  Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million—  Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million—  Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q2 FY 2025") ended March 31, 2025 and six months ("YTD FY 2025") ended March 31, 2025. Revenue by Segment (in millions of USD)   Three Months EndedMarch 31, %change Six Mo

      5/7/25 4:05:00 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025

      WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, on Wednesday, May 7, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-245-3047 (Domestic)1-203-518-9765 (International)INOTIV

      4/23/25 4:05:00 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Inotiv, Inc. to Report Fiscal 2025 First Quarter Financial Results and Host Conference Call on Wednesday, February 5, 2025

      WEST LAFAYETTE, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, on Wednesday, February 5, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-579-2543 (Domestic)1-785-424-1789 (International)I

      1/22/25 4:05:00 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NOTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)

      SC 13D/A - Inotiv, Inc. (0000720154) (Subject)

      4/3/24 10:47:10 AM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)

      SC 13D/A - Inotiv, Inc. (0000720154) (Subject)

      10/6/22 12:24:15 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by Inotiv Inc. (Amendment)

      SC 13D/A - Inotiv, Inc. (0000720154) (Subject)

      9/20/22 9:00:08 AM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $NOTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Coelho Mary Theresa sold $12,916 worth of shares (5,500 units at $2.35), decreasing direct ownership by 7% to 74,303 units (SEC Form 4)

      4 - Inotiv, Inc. (0000720154) (Issuer)

      4/2/25 4:32:56 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • President and CEO Leasure Robert Jr. was granted 429,730 shares, increasing direct ownership by 45% to 1,386,322 units (SEC Form 4)

      4 - Inotiv, Inc. (0000720154) (Issuer)

      3/18/25 5:39:56 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Director Neff R Matthew was granted 39,392 shares, increasing direct ownership by 34% to 155,102 units (SEC Form 4)

      4 - Inotiv, Inc. (0000720154) (Issuer)

      3/18/25 4:15:52 PM ET
      $NOTV
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care